Sareum Holdings PLC - Cambridge, England-based biotechnology company focused on developing kinase inhibitors for autoimmune disease & cancer - Says it is pleased by the publication of data from the Phase 1/2 trial of SRA737 as a combination treatment for advanced cancers in the medical journal, Clinical Cancer Research.

SRA737 is a clinical-stage oral, selective checkpoint kinase one inhibitor that targets cancer cell replication and DNA damage repair mechanisms. This is the first peer-reviewed publication of clinical data on trials conducted using a Chk1 inhibitor in combination with a novel, lower dose of gemcitabine compared to standard of care.

Chief Executive Officer Tim Mitchell says: ‘As we assess opportunities to further develop this asset, subject to discussions with our partners, this is an encouraging development which reinforces our confidence in the potential of SRA737.’

Current stock price: 81.00 pence, down 5.8% on Monday in London

12-month change: down 59%

Copyright 2022 Alliance News Limited. All Rights Reserved.